Novartis announced the launch of its FocalView app, which will provide the opportunity for patients to participate in ophthalmology clinical trials from home.
FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients.
Novartis believes the app offers tremendous benefit for the ophthalmic community, as patients with eye diseases are often not as mobile. The drugmaker hopes that the app will reduce barriers to trial participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.
Read the press release